{"url_path":"/sec/med/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/910329/0001628280-26-039293-index.html","accession_number":"0001628280-26-039293","cik":"0000910329","ticker":"MED","issuer_name":"MEDIFAST INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/910329/0001628280-26-039293-index.html","primary_entity_key":"0000910329","primary_entity_name":"MEDIFAST INC"},"word_count":78,"has_tables":true,"body_markdown":"Item 9.01.    Financial Statements and Exhibits.\n\n(d)\n\nExhibits.\n\n10.1\n[Separation Agreement by and between Jason Groves and Jason Pharmaceuticals, Inc.](separationagreement.htm)\n\n104.1Cover Page Interactive Data File (embedded within the Inline XBRL Document)\n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nMEDIFAST, INC.\n\nBy:/s/ James P. Maloney\n\nJames P. Maloney\n\nChief Financial Officer\n\nDated: June 1, 2026"}